Narrow search
Showing 1 - 10 of 111
Cover Image
A Probability Approach to Pharmaceutical Demand and Price Setting : Does the Identity of the Third-Party Payer Matters for Prescribing Doctors?
Dalen, Dag Morten - 2011
structural model for the three drugs, covering demand and price setting, is estimated in a joint maximum likelihood approach. We …
Persistent link: https://www.econbiz.de/10013118139
Cover Image
Margins and Market Shares : Pharmacy Incentives for Generic Substitution
Brekke, Kurt Richard - 2013
generics and their market shares. This relationship is stronger for pharmaceuticals under reference pricing rather than …
Persistent link: https://www.econbiz.de/10013088216
Cover Image
The Impact of Pharmaceutical Innovation on Longevity and Medical Expenditure in Sweden, 1997-2010 : Evidence from Longitudinal, Disease-Level Data
Lichtenberg, Frank R.; Pettersson, Billie - 2021
We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is estimated to have increased mean age at death by...
Persistent link: https://www.econbiz.de/10013315886
Cover Image
Reference Pricing, Competition, and Pharmaceutical Expenditures : Theory and Evidence from a Natural Experiment
Brekke, Kurt Richard; Holmas, Tor Helge; Straume, Odd Rune - 2021
We study the impact of regulation on competition between brand-names and generics and pharmaceutical expenditures using a unique policy experiment in Norway, where reference pricing (RP) replaced price cap regulation in 2003 for a sub-sample of off-patent products. First, we construct a vertical...
Persistent link: https://www.econbiz.de/10013316129
Cover Image
Choosing Among Competing Blockbusters : Does the Identity of the Third-Party Payer Matter for Prescribing Doctors?
Dalen, Dag Morten - 2010
TNF-alpha inhibitors represent one of the most important areas of biopharmaceuticals by sales, with three blockbusters accounting for 8% of total pharmaceutical sale in Norway. With use of a unique natural policy experiment in Norway, this paper examines to what extent the identity of the...
Persistent link: https://www.econbiz.de/10013136585
Cover Image
Wages Anatomy. Labor Supply of Nurses and a Comparison with Physicians
Andreassen, Leif - 2014
are young (less than physicians), but there is also a weak tendency of higher mobility again when they are approaching … physicians). These low elasticities shadow for stronger responses, shifting labor away from part time jobs in the public and … physicians the impact is stronger …
Persistent link: https://www.econbiz.de/10013040495
Cover Image
Competition and Physician Behaviour : Does the Competitive Environment Affect the Propensity to Issue Sickness Certificates?
Brekke, Kurt Richard - 2017
Competition among physicians is widespread, but compelling empirical evidence on the impact on service provision is …
Persistent link: https://www.econbiz.de/10012944981
Cover Image
Do Medical Doctors Respond to Economic Incentives?
Andreassen, Leif; Di Tommaso, Maria L.; Strøm, Steinar - 2021
A longitudinal analysis of married physicians labor supply is carried out on Norwegian data from 1997 to 1999. The … model utilized for estimation implies that physicians can choose among 10 different job packages which are a combination of … cut moves married physicians towards full time job packages, in particular to full time jobs in the private sector. But …
Persistent link: https://www.econbiz.de/10013315919
Cover Image
Sustainable Reimbursements : Towards a Unified Framework for Pricing Drugs with Significant Uncertainties
Chassang, Sylvain - 2018
Recent political events have thrust the bulk negotiation of drug prices by Medicare and Medicaid back into the spotlight. Yet, even if politically feasible, there is no clear framework for negotiating prices of new drugs with uncertain target populations — for example, due to imprecise...
Persistent link: https://www.econbiz.de/10012925248
Cover Image
Is Medicines Parallel Trade 'Regulatory Arbitrage'?
Costa-Font, Joan - 2015
In the European Union, medicines are regulated products subject to both single market (e.g., regional exhaustion of property rights) and country specific health care regulations (e.g., medicines pricing). This gives rise to parallel trade (PT), a phenomenon that takes place when a patented...
Persistent link: https://www.econbiz.de/10013028783